Changchun High-tech: Subsidiary GenSci161 Injection Drug Registration Clinical Trial Application Accepted

Changchun High-tech announces that its controlling subsidiary, Jinsai Pharmaceutical, has received the “Acceptance Notice” issued by the National Medical Products Administration. The domestic clinical trial application for Jinsai Pharmaceutical’s GenSci161 injection has been accepted. GenSci161 injection is a Class 1 biological therapeutic drug independently developed by Jinsai Pharmaceutical, intended for the treatment of endometriosis and suppurative hidradenitis.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)